Sullivan Nicolaides Pathology Revenue and Competitors

AU

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Sullivan Nicolaides Pathology's estimated annual revenue is currently $484.6M per year.(i)
  • Sullivan Nicolaides Pathology's estimated revenue per employee is $378,000

Employee Data

  • Sullivan Nicolaides Pathology has 1282 Employees.(i)
  • Sullivan Nicolaides Pathology grew their employee count by 5% last year.

Sullivan Nicolaides Pathology's People

NameTitleEmail/Phone
1
Regional ManagerReveal Email/Phone
2
Clinical Trials ManagerReveal Email/Phone
3
Information Technology Client Services ManagerReveal Email/Phone
4
Facilities ManagerReveal Email/Phone
5
Gold Coast North Laboratory ManagerReveal Email/Phone
6
Medical ScientistReveal Email/Phone
7
PhlebotomistReveal Email/Phone
8
Specimen CollectorReveal Email/Phone
9
Laboratory AssistantReveal Email/Phone
10
DermatopathologistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.3M34N/AN/AN/A
#2
$26.2M97N/AN/AN/A
#3
$71.6M2418%N/AN/A
#4
$34M1261%N/AN/A
#5
$47.8M161-7%N/AN/A
#6
$65.9M2224%N/AN/A
#7
$30M111-12%N/AN/A
#8
$295.6M7828%N/AN/A
#9
$24M8919%N/AN/A
#10
$34.6M12810%N/AN/A
Add Company

What Is Sullivan Nicolaides Pathology?

A leading provider of pathology services.

keywords:N/A

N/A

Total Funding

1282

Number of Employees

$484.6M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sullivan Nicolaides Pathology News

2022-04-19 - NSW headed for ‘significant flu epidemic’ as cases triple

The Royal College of Pathologists of Australasia has warned the 2022 ... of the department of microbiology at Sullivan Nicolaides Pathology.

2022-04-19 - Experts Warn Australians Are More Vulnerable To Influenza ...

RCPA Fellow Dr Jenny Robson, Pathologist-in-Charge of the Department of Microbiology Sullivan Nicolaides Pathology, said the influenza virus...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$395.8M128556%N/A
#2
$369.4M128711%N/A
#3
$431M128815%N/A
#4
$487.6M12908%N/A
#5
$184.5M129213%N/A